Document is current

Any future updates will be listed below

Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study

Crossref DOI link: https://doi.org/10.1186/1546-0096-13-S1-O58

Published Online: 2015-09-28

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark